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Placement of implantable cardioverter-defibrillators (ICDs) is increasing in frequency due to 
their indication for the prevention of sudden cardiac death in patients prone to life-threatening 
arrhythmias. Primary care physicians should be aware of the possible complications so they can 
treat their patients appropriately. This article describes a rare case of chronic unilateral breast 




Tetralogy of Fallot, automated implantable cardioverter-defibrillator, young adult, male, breast 
enlargement, pacemaker complication  
 
Introduction    
There are many causes of male breast enlargement. Male breast cancer accounts for less than 1% 
of breast cancers.1 Benign processes include sebaceous cysts, lipomas, hematomas, excess 
adipose tissue, and gynecomastia.2 Gynecomastia, the most common cause of male breast 
enlargement, is defined as the benign enlargement of glandular tissue. caused by the effects of an 
elevated estrogen to androgen ratio.2 Physiological gynecomastia occurs during three life stages: 
the neonatal period, puberty, and over 60 years of age.3 Pathological gynecomastia can be 
caused by a range of conditions such as endocrine dysfunction, tumors, renal failure, cirrhosis, 
and medication.3  
 
Iatrogenic causes of breast enlargement are less well-documented. To the best of our knowledge, 
unilateral gynecomastia has not previously been reported as a complication of implantable 
cardioverter-defibrillator (ICD) placement. Complications arise in about thirty percent of 
patients who receive ICDs.4 We report a young male patient with Tetralogy of Fallot who 
developed left-sided breast enlargement following ICD placement.  
 
Case 
The patient is a 29-year-old African American male with a history of Tetralogy of Fallot (TOF) 
with pulmonary atresia and tricuspid regurgitation, who had multiple surgeries including a 
Blalock Taussig shunt in 1984, a ventricular septal defect closure in 1986, aortic root homograft 
conduit replacement in 1988, and pulmonary valve replacement with Carpentier-Edwards 
heterograft in 1992. His cardiologist prescribed medication after multiple unsuccessful ablation 
attempts for atrial fibrillation and flutter. In 2010, an ICD was implanted due to syncope related 
to Infra-Hisian conduction disease. He complained of painless enlargement of his left breast 
since receiving the ICD. Medications included diltiazem, metoprolol, dabigatran, and dofetilide. 
He denied alcohol or drug abuse. He is sexually active with no erectile dysfunction. Record 
review revealed he was taking sotalol and not diltiazem at the time breast enlargement began. 
One year prior to our visit, the patient had a CT chest to evaluate the breast enlargement which 
revealed gynecomastia.  
On physical examination, the patient had a blood pressure of 112/74 mm Hg and a pulse of 86 
beats per minute. His BMI was 32. His anterior chest wall revealed well-healed median 
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sternotomy and ICD scars. The left breast was significantly larger than the right breast (Figure 
1). There was no tenderness, discrete mass, or nipple discharge. Auscultation revealed a 
previously noted systolic murmur heard best over the right upper sternal border. His testicular 
exam was normal.  
Bloodwork including prolactin (7.3 ng/ml (2.1-17.7 ng/ml)), testosterone (433 ng/dl (348-1197 
ng/dl)), and TSH (2.089 mIU/L (0.37-4.42 mIU/L)) was normal. The patient refused an 
ultrasound and mammogram. The primary care physician contacted the surgeon who placed the 
ICD, who thought it might be a seroma, and stated he would repair it when the battery needed 
changing. Four months later, the patient had a malfunctioning right ICD lead replaced. The 
operative report does not mention a seroma or abnormal location of the ICD outside of the 
pocket and upon the follow-up exam, the breast enlargement was unchanged. The patient moved 





    
Figure 1. Evidence of left-sided breast enlargement, post-ICD placement 
Discussion 
To the best of our knowledge, breast enlargement following ICD placement has not previously 
been reported. The differential diagnosis for new unilateral breast enlargement includes 
inflammatory breast carcinoma, lymphatic or venous obstruction, mastitis, fat necrosis, 
hormonal imbalance, and congestive heart failure.5 We considered hormonal imbalance in our 
patient, but he had no symptoms of hormone excess such as pain associated with breast 
enlargement or erectile dysfunction. Although there is fair quality data that connects diltiazem to 
gynecomastia, the patient was not taking this when his breast enlargement began.6 Our clinical 
diagnosis is gynecomastia, which is consistent with the appearance on our patient’s CT scan. We 
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believe the patient’s gynecomastia was caused by obesity but was worsened by concomitant 
lymphatic obstruction from multiple surgeries. The authors admit we have no direct proof that 
this is the diagnosis; however, we have a CT scan showing gynecomastia, an operative report 
showing no abnormality with the ICD pocket, and the temporal relationship of breast 
enlargement to the procedure.  
 
Gynecomastia is more common in elderly men than in younger men and is often related to a 
clinical cause, including medications, an underlying disease, or an idiopathic condition.7 Classic 
gynecomastia does not require mammography and is symmetrically placed under the nipple, firm 
or rubbery upon palpation, and most often bilateral. This is opposed to breast cancer, which is 
most often a non-symmetrical, unilateral, fixed mass. Our patient did not have the classic lump 
under the nipple on exam, and while mammography and ultrasound were considered due to the 
rapid onset, the patient refused this evaluation. Laboratory tests such as testosterone, prolactin, 
luteinizing hormone, estradiol, human chorionic gonadotropin, thyroid, liver, and kidney 
function can be performed as part of the evaluation of gynecomastia if there is recent onset 
breast enlargement and breast tenderness.  
 
Our patient’s gynecomastia occurred immediately following the placement of his ICD. The most 
common ICD-related complication encountered in the TOF population is inappropriate shocks 
that are not life-threatening. The DAI-T4F National Registry of all TOF subjects implanted with 
an ICD between 2005 and 2016 showed that ≥ 1 complication occurred in 40 patients (39%), 
including inappropriate shock (n = 26), major pocket hematoma (n = 1), lead dysfunction (n = 
15), infection (n = 6), reflex sympathetic dystrophy (n = 2), and device failure needing 
reintervention (n = 3).8 Our patient also experienced lead dysfunction, which is a known 




As an increasing number of patients receive ICDs, physicians should be aware of the possible 
complications to allow for appropriate and timely treatment. We present this case of unilateral 
breast enlargement following ICD placement to bring awareness to this potential complication, 
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